ArticleBMC cancer2026
The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRadiological assessment based on RECIST criteria has limited accuracy in evaluating chemotherapy response in advanced pancreatic ductal adenocarcinoma (PDAC), particularly in patients classified as stable disease. Additional clinically accessible biomarkers are needed to better stratify treatment response and prognosis in this population.
methodsThis study retrospectively included patients with advanced PDAC who received first-line chemotherapy and completed an 8-week response assessment. Contrast-enhanced CT and serum CA19-9 were evaluated every 8 weeks for disease surveillance. The primary endpoints were progression-free survival (PFS) and overall survival (OS).
resultsOf 182 patients included, 117 (64.3%), 21 (11.5%), and 44 (24.2%) patients were classified into SD, partial response (PR), and progressive disease (PD) at the first radiological evaluation. The SD cohorts presented OS similar to the PR cohort (P = 0.348). In SD patients with elevated baseline CA19-9 levels, the cohort with a 30% reduction of baseline CA19-9 levels was defined as the CA19-9 response group. Compared with the nonresponse group (decreased < 30% or increased CA19-9 cohorts), the response group presented significantly better PFS (P < 0.001) and OS (P = 0.010).
conclusionsAfter 8 weeks of first-line chemotherapy, most patients with advanced PDAC were classified as SD and exhibited survival outcomes comparable to those with partial response. In patients with stable disease and elevated baseline CA19-9 levels, a ≥ 30% reduction in CA19-9 provided additional prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.